公司资料
Morphic Holding, Inc. 股价、新闻与催化剂
已退市
- 股票代码:
- MORF
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
目前无法获取 MORF 的收盘价变动背景。
公司概览
业务概览
Morphic was an integrin-focused biotechnology company with a pipeline in inflammatory and gastrointestinal disease before being acquired by Eli Lilly.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ prior to acquisition, it sat in specialty biotechnology.
商业模式特征
The company was driven by novel biology, early clinical data, and the value of its integrin platform.
生物医药行业定位
Morphic was a targeted immunology name and now belongs to biotech M&A history.
未来催化剂
- Morphic is now mostly a closeout and acquisition story after the Lilly deal, so the catalysts are integration and any remaining corporate milestone. The market is not treating it like a live standalone pipeline name anymore.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。